Skip to main content
Supriya Lifescience Limited logo

Supriya Lifescience Limited — Investor Relations & Filings

Ticker · SUPRIYA ISIN · INE07RO01027 LEI · 894500RBVJX1EOJP0Y02 BSE.NS Manufacturing
Open in API
Filings indexed 475 across all filing types
Latest filing 2023-08-02 Regulatory Filings
Country IN India
Listing BSE.NS SUPRIYA

About Supriya Lifescience Limited

https://www.supriyalifescience.com

Supriya Lifescience Limited is a research-driven manufacturer of Active Pharmaceutical Ingredients (APIs) with a focus on diverse therapeutic segments. The company specializes in the production of antihistamines, anti-allergics, vitamins, anesthetics, and anti-asthmatics. Its core product portfolio includes Chlorpheniramine Maleate, Ketamine Hydrochloride, and Salbutamol Sulphate, maintaining a significant global market share in these niche categories. Operating with a strong emphasis on backward integration, the firm ensures supply chain reliability and cost efficiency. The manufacturing infrastructure is compliant with international regulatory standards, including approvals from the USFDA, EDQM, and PMDA. Supriya Lifescience serves a broad international clientele across more than 100 countries, catering to both regulated and semi-regulated markets through its advanced R&D capabilities and commitment to quality excellence.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new collaboration and technology licensing agreement between Supriya Lifescience Ltd and Plasma Nutrition, Inc. It is addressed to stock exchanges and mentions compliance with SEBI Listing Regulations. The content focuses on the business partnership and product introduction rather than financial results, regulatory filings, or management changes. There is no indication of financial statements, voting results, or report attachments. The document is a corporate announcement of a strategic collaboration, which fits best under the category of a general regulatory announcement or miscellaneous filing that does not fit other specific categories. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-08-02 English
Shareholders meeting
Regulatory Filings
2023-08-01 English
Shareholders meeting
Regulatory Filings
2023-08-01 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) informing about an upcoming earnings call scheduled for August 4, 2023, to discuss the operational and financial performance for Q1 FY 2023-24. It includes details about the call, participants, and access numbers. There is no actual financial data or results presented in this document; it is merely an announcement of the earnings call event. According to the classification rules, announcements about earnings calls are not the earnings release itself but notifications about the call. Therefore, this document fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement rather than an Earnings Release (ER) or Call Transcript (CT).
2023-07-28 English
Board Meeting — SUPRIYA LIFESCIENCE LIMITED has informed the Exchange about Board Meeting to be held on 03-Aug-2023 to inter-alia consider and approve the Unaudited Financial results of the Company f…
Regulatory Filings
2023-07-27 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a letter dated July 27, 2023, addressed to stock exchanges (BSE and NSE) informing them about an upcoming Board Meeting scheduled for August 3, 2023. The purpose of the meeting is to consider and approve the unaudited financial results for the quarter ended June 30, 2023. The letter also mentions the closure of the trading window in compliance with insider trading regulations. The document is an announcement of a board meeting and related compliance information, not the financial results themselves or a detailed report. It does not contain financial data or detailed management discussion. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of board meetings and related management information.
2023-07-27 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.